Progenics

The official site for Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. Nasdaq: PGNX

[Progenics @Progenics]

Progenics Stockholders Approve Merger with Lantheus https://t.co/pwdldKBP4u

[Progenics @Progenics]

Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program https://t.co/AxrbdGvpt0

[Progenics @Progenics]

Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update https://t.co/FTHUrvR2MU

[Progenics @Progenics]

Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7 https://t.co/JtVKu57Wgo

[Progenics @Progenics]

PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS https://t.co/0ctq4zrKpF

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU) https://t.co/ixWvGcJCJB

[Progenics @Progenics]

Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review https://t.co/ZWEOpdrl4H

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting https://t.co/OWZ1w4Pf2e

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint https://t.co/ivLfak0wWV

[Progenics @Progenics]

Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd https://t.co/6ULFwZVke9

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting https://t.co/7cbSovmBhZ

[Progenics @Progenics]

Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer https://t.co/fydPYY7TsV

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results https://t.co/PIsn9uWEar

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations https://t.co/NANWu2nnJR

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update https://t.co/ijRqSOWFk5

[Progenics @Progenics]

CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) https://t.co/qukEr8Pyx6

[Progenics @Progenics]

Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer https://t.co/bZCuJOy7Ue

[Progenics @Progenics]

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 https://t.co/qI3RnxN6uU

[Progenics @Progenics]

Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis https://t.co/JEzscvETCa

[Progenics @Progenics]

Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial https://t.co/eeobX1SBrz